EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Primary Small Cell Neuroendocrine Carcinoma of the Sublingual Gland Treated With Definitive Chemoradiotherapy: A Case Report

Taka-Aki Tokura iD, Hironari Dehari, Koyo Nishiyama, Sho Miyamoto iD, Takanori Sasaki iD, Kazuhiro Ogi iD, Taro Sugawara, Masanori Someya, Kohichi Takada iD, Hiroyuki Kitajo, Akihiro Miyazaki iD

Clinical Case Reports · 2026-05 · 14 (5)

DOI: 10.1002/ccr3.72565 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Case Reports, online erschienen am 24.04.2026. Verfasst von Taka-Aki Tokura und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Surgery Sapporo Medical University School of Medicine Sapporo Japan. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary sublingual gland small cell neuroendocrine carcinoma (SCNEC) is extremely rare, with only one prior case reported, and no site‐specific standard of care has been established. We report a case of primary sublingual gland SCNEC treated with definitive concurrent chemoradiotherapy (CRT). A 69‐year‐old man presented with a 21 × 15‐mm right sublingual mass showing fluorodeoxyglucose uptake (SUVmax 9.9) on PET/CT. No nodal or distant disease was found. Biopsy revealed small cell morphology positive for INSM1/synaptophysin and pan‐cytokeratin, with a high Ki‐67 index (> 95%). IMRT delivered 70 Gy in 35 fractions to the primary tumor with elective bilateral nodal irradiation (levels I–V, 46 Gy). Cisplatin (80 mg/m 2 ; day 1) and etoposide (100 mg/m 2 ; days 1–3) were administered every 3 weeks for four cycles. Grade 3 oral mucositis and grade 2 neutropenia resolved. At 24 months post‐CRT, the patient remains disease‐free with preserved daily function. Definitive concurrent CRT appears to be a feasible and effective organ‐preserving treatment option for limited‐stage primary sublingual gland SCNEC, with durable disease control at 24 months in this case.

Schlagwörter

Stichwörter der Autor:innen

definitive chemoradiotherapyextrapulmonary small cell carcinomahead and neck small cell carcinomasmall cell neuroendocrine carcinomasublingual gland

Autor:innen und Institutionen

  • Department of Oral Surgery Sapporo Medical University School of Medicine Sapporo Japan.
  • Department of Surgical Pathology Sapporo Medical University School of Medicine Sapporo Japan.
  • Department of Radiology Sapporo Medical University School of Medicine Sapporo Japan.
  • Division of Medical Oncology, Department of Internal Medicine Sapporo Medical University School of Medicine Sapporo Japan.
  • Sapporo Teine Dental and Oral Surgery Clinic Sapporo Japan.

ORCID-Profile: Taka-Aki Tokura, Sho Miyamoto, Takanori Sasaki, Kazuhiro Ogi, Kohichi Takada, Akihiro Miyazaki

Zitieren

APA

Tokura, T. A., Dehari, H., Nishiyama, K., Miyamoto, S., Sasaki, T., Ogi, K., Sugawara, T., Someya, M., Takada, K., Kitajo, H., & Miyazaki, A. (2026). Primary Small Cell Neuroendocrine Carcinoma of the Sublingual Gland Treated With Definitive Chemoradiotherapy: A Case Report. Clinical Case Reports, 14(5). https://doi.org/10.1002/ccr3.72565

Vancouver

Tokura TA, Dehari H, Nishiyama K, Miyamoto S, Sasaki T, Ogi K, et al. Primary Small Cell Neuroendocrine Carcinoma of the Sublingual Gland Treated With Definitive Chemoradiotherapy: A Case Report. Clinical Case Reports. 2026;14(5). doi:10.1002/ccr3.72565

BibTeX
@article{Tokura2026,
  author = {Tokura, Taka-Aki and Dehari, Hironari and Nishiyama, Koyo and Miyamoto, Sho and Sasaki, Takanori and Ogi, Kazuhiro and Sugawara, Taro and Someya, Masanori and Takada, Kohichi and Kitajo, Hiroyuki and Miyazaki, Akihiro},
  title = {Primary Small Cell Neuroendocrine Carcinoma of the Sublingual Gland Treated With Definitive Chemoradiotherapy: A Case Report},
  journal = {Clinical Case Reports},
  year = {2026},
  volume = {14},
  number = {5},
  doi = {10.1002/ccr3.72565}
}
Kostenlos starten →